New Drugs Hailed as a 'Major Shift' in Addressing Antibiotic-Resistant Gonorrhoea

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to health experts.

An International Health Concern

Gonorrhoea infections are escalating worldwide, with data suggesting more than 82 million instances each year. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, the spread of superbugs and the very limited treatment choices at this time.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to major issues, including infertility. Scientists anticipate that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in close succession. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This milestone marks a major breakthrough in the treatment of superbug gonorrhoea, which previously has been outpacing medical innovation.”

Testing Results and Worldwide Availability

According to findings released by a major medical journal, zoliflodacin eradicated more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which uses an injection and a pill. The trial enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the rights to license and sell the drug in numerous developing nations.

Doctors directly involved have voiced hope. The availability of a single-dose, oral treatment like this is seen as a "critical tool" for managing the epidemic. This is considered essential to lessen the impact of the disease for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.